Dermapharm Holding SE/€DMP
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Dermapharm Holding SE
Dermapharm Holding SE is a pharmaceutical company based in Germany, specializing in the development, production, and commercialization of off-patent branded pharmaceuticals. The company focuses on several key product segments, including dermatological and allergy products, vitamins, and food supplements. Established in 1991, Dermapharm has developed a diversified product portfolio with over 900 marketing authorizations. It operates production facilities in Europe and maintains a strong sales presence in Germany and other European countries. The company's strategic positioning is bolstered by its vertically integrated business model, which enables efficient product development and manufacturing processes.
Ticker
€DMP
Sector
Primary listing
XETRA
Industry
Pharmaceuticals
Headquarters
Employees
3,610
ISIN
DE000A2GS5D8
Website
DMP Metrics
BasicAdvanced
€1.9B
18.29
€1.92
1.31
€0.90
2.56%
Price and volume
Market cap
€1.9B
Beta
1.31
52-week high
€41.40
52-week low
€29.37
Average daily volume
23K
Dividend rate
€0.90
Financial strength
Current ratio
2.055
Quick ratio
0.799
Long term debt to equity
142.595
Total debt to equity
154.975
Dividend payout ratio (TTM)
45.74%
Interest coverage (TTM)
3.87%
Profitability
EBITDA (TTM)
248.243
Gross margin (TTM)
62.43%
Net profit margin (TTM)
8.66%
Operating margin (TTM)
18.02%
Effective tax rate (TTM)
35.45%
Revenue per employee (TTM)
€330,000
Management effectiveness
Return on assets (TTM)
6.40%
Return on equity (TTM)
16.57%
Valuation
Price to earnings (TTM)
18.29
Price to revenue (TTM)
1.58
Price to book
2.97
Price to tangible book (TTM)
-4.29
Price to free cash flow (TTM)
14.433
Free cash flow yield (TTM)
6.93%
Free cash flow per share (TTM)
243.75%
Dividend yield (TTM)
2.56%
Forward dividend yield
2.56%
Growth
Revenue change (TTM)
6.20%
Earnings per share change (TTM)
83.15%
3-year revenue growth (CAGR)
6.96%
3-year earnings per share growth (CAGR)
-21.06%
3-year dividend per share growth (CAGR)
-25.42%
Bulls say / Bears say
Dermapharm's 'Branded pharmaceuticals' segment achieved a 9.8% revenue increase to EUR 585.1 million in 2024, driven by strong growth within Germany and international expansion. (finanzwire.com)
The company reported an unadjusted EBITDA increase of 10.2% to EUR 308.9 million in 2024, surpassing previous guidance and indicating robust operational performance. (webdisclosure.com)
Dermapharm's strategic focus on innovation, internationalization, and targeted acquisitions has proven successful, as evidenced by the successful integration of new companies and continuous expansion of its product portfolio. (webdisclosure.com)
Dermapharm expects consolidated revenue to stagnate in 2025, with projections between EUR 1,160 million and EUR 1,200 million, indicating potential challenges in sustaining growth momentum. (marketscreener.com)
The 'Other healthcare products' segment experienced a 4.7% revenue decline to EUR 354.4 million in 2024, attributed to prior sales and price adjustments in 2023 affecting 2024's financial outcomes. (finanzwire.com)
Regulatory changes have led to high statutory discounts in the 'Parallel import business' segment, negatively impacting earnings despite a slight revenue growth of 4.5%. (finanzwire.com)
Data summarised monthly by Lightyear AI. Last updated on 28 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Dermapharm Holding SE stock?
Dermapharm Holding SE (DMP) has a market cap of €1.9B as of July 05, 2025.
What is the P/E ratio for Dermapharm Holding SE stock?
The price to earnings (P/E) ratio for Dermapharm Holding SE (DMP) stock is 18.29 as of July 05, 2025.
Does Dermapharm Holding SE stock pay dividends?
Yes, the Dermapharm Holding SE (DMP) stock pays dividends to shareholders. As of July 05, 2025, the dividend rate is €0.9 and the yield is 2.56%. Dermapharm Holding SE has a payout ratio of 45.74% on a trailing twelve-month basis.
When is the next Dermapharm Holding SE dividend payment date?
The next Dermapharm Holding SE (DMP) dividend payment date is unconfirmed.
What is the beta indicator for Dermapharm Holding SE?
Dermapharm Holding SE (DMP) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.